Skin Conditions & Dermatology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

This Phase 3 clinical trial studied tildrakizumab injections for adults with moderate-to-severe plaque psoriasis, a condition that causes red, scaly patches on the skin. With over 1000 participants enrolled, the results are now available and suggest that tildrakizumab may help reduce symptoms and improve skin clearing while maintaining safety. This could offer patients a new treatment option that is effective and has manageable side effects.

Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation

This Phase 3 study is investigating a new combination of dupilumab and berahyaluronidase alfa for adolescents and adults with moderate-to-severe atopic dermatitis, a common inflammatory skin condition. Although the trial is not yet recruiting, it aims to see if this combined treatment could be more tolerable or effective than current dupilumab options. If successful, it might provide a better treatment experience for people managing this often persistent condition.

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Completed in China with over 200 participants, this Phase 3 trial tested jaktinib hydrochloride tablets as an oral treatment for moderate to severe atopic dermatitis. The study focused on long-term safety and benefits, offering hope for a new therapy that could improve symptom control and quality of life. Oral medications like jaktinib may provide a convenient alternative to injections or topical treatments.

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

This separate Phase 3 study also evaluated jaktinib tablets in adults with moderate to severe atopic dermatitis, involving more than 400 participants in China. Results from this completed trial could support jaktinib as a new oral option to help reduce the itching and inflammation that affect daily life for many patients. Having multiple studies showing positive outcomes strengthens the potential for this medication.

Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo

In Phase 2, this upcoming trial will test TEV-53408 injections in adults with Non-Segmental Vitiligo, a condition that causes loss of skin color in patches. Although not yet recruiting, the study plans to enroll over 1000 participants to see if the treatment can restore skin pigmentation. A new therapy like TEV-53408 could help improve appearance and confidence for many people living with vitiligo.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.